These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15588691)

  • 1. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC; Hommes DW
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory peptides and proteins in inflammatory bowel disease.
    Veljaca M
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1387-94. PubMed ID: 11890353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic inflammatory bowel disease--pathogenic concepts and therapeutic perspectives].
    Madsen JR
    Ugeskr Laeger; 2000 Mar; 162(10):1361-6. PubMed ID: 10745672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory bowel disease: potential therapeutic strategies.
    Nielsen OH; Vainer B; Bregenholt S; Claësson MH; Bishop PD; Kirman I
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):267-81. PubMed ID: 9740355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
    Podolsky DK
    Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy of inflammatory bowel disease].
    Jojić N
    Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cytokine-targeted therapies and intestinal inflammation.
    Waldner MJ; Neurath MF
    Curr Opin Pharmacol; 2009 Dec; 9(6):702-7. PubMed ID: 19674937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis as a therapeutic tool in IBD?
    Lügering A; Lebiedz P; Koch S; Kucharzik T
    Ann N Y Acad Sci; 2006 Aug; 1072():62-77. PubMed ID: 17057191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines and inflammatory bowel disease.
    Anand AC; Adya CM
    Trop Gastroenterol; 1999; 20(3):97-106. PubMed ID: 10695414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
    Van Assche G; Vermeire S; Rutgeerts P
    Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone in inflammatory bowel disease.
    De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.